Will Johnson & Johnson (JNJ) Gain Value?

Johnson & Johnson (NYSE: JNJ) stock is losing value these days amid growth concerns regarding medicine Zytiga and rheumatoid arthritis drug Remicade. But some analysts believe that J&J stock is undervalued. The company’s pharmaceuticals segment which is responsible for about half of its total revenue increased by 19% in terms of sales.

Johnson & Johnson ’s total revenue came in at $20 billion, surpassing Street’s estimate of $19.46 billion. J&J’s cancer division also looks strong. The company’s cancer division revenue in the first quarter increased by 45% to $2.31 billion. Analysts think that J&J stock will regain value in the near future.

Over the current book year the total revenue will be 81,51 billion USD (consensus estimates). This is slightly more than 2017's revenue of 76,45 billion USD.

Historical revenues and results Johnson & Johnson plus estimates 2018

The analysts expect for 2018 a net profit of 21,96 billion USD. The majority of the analysts expects for this year a profit per share of 8,13 USD. The PE-ratio therefore is 15,71.

For this year most of the analysts expect a dividend of 3,59 USD per share. Johnson & Johnson 's dividend yield thus equals 2,81 percent. The average dividend yield of the health care companies equals a limited 1 percent.

Recent target prices around 140 USD

The most recent recommendations for the health care company are from Jefferies & Co., Sanford C. Bernstein & Co and Independent Research.

Based on the current number of shares Johnson & Johnson 's market capitalization equals 345,78 billion USD.

At 16.15 the stock trades 0,92 percent lower at 127,76 USD.

Historical stock prices Johnson & Johnson

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.